BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 17512837)

  • 1. Ovarian suppression for early breast cancer.
    Wilcken N; Stockler M
    Lancet; 2007 May; 369(9574):1668-70. PubMed ID: 17512837
    [No Abstract]   [Full Text] [Related]  

  • 2. Which is the appropriate adjuvant endocrine therapy for premenopausal patients with breast cancer?
    Petrelli F; Barni S
    Clin Breast Cancer; 2015 Jun; 15(3):169-70. PubMed ID: 25600162
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant endocrine therapy in premenopausal women with breast cancer.
    González Martín A; de la Cruz S; Márquez R
    Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():43-7. PubMed ID: 20711666
    [No Abstract]   [Full Text] [Related]  

  • 4. Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
    Pritchard KI
    Oncology (Williston Park); 2009 Jan; 23(1):27-33. PubMed ID: 19283918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian ablation as adjuvant therapy for early-stage breast cancer.
    Pritchard KI
    Cancer Treat Res; 1998; 94():158-80. PubMed ID: 9587687
    [No Abstract]   [Full Text] [Related]  

  • 6. [Adjuvant endocrine therapy in breast cancer].
    Huober J; Thürlimann B
    Ther Umsch; 2008 Apr; 65(4):193-200. PubMed ID: 18622910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer.
    Cianfrocca M; Wolff AC
    Oncology (Williston Park); 2007 Jan; 21(1):63-9; discussion 69, 72, 75 passim. PubMed ID: 17313157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant endocrine therapy for premenopausal hormone receptor-positive breast cancer; much done, more to do.
    Higgins MJ; Wolf AC
    Oncology (Williston Park); 2009 Jan; 23(1):40, 42, 44. PubMed ID: 19283920
    [No Abstract]   [Full Text] [Related]  

  • 10. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women.
    Parton M; Smith IE
    J Clin Oncol; 2008 Feb; 26(5):745-52. PubMed ID: 18258982
    [No Abstract]   [Full Text] [Related]  

  • 11. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
    Conte B; Poggio F; Del Mastro L
    Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian Suppression in Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    Pan K; Bosserman LD; Chlebowski RT
    J Clin Oncol; 2019 Apr; 37(11):858-861. PubMed ID: 30742565
    [No Abstract]   [Full Text] [Related]  

  • 13. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.
    Pritchard KI
    J Clin Oncol; 2005 Aug; 23(22):4850-2. PubMed ID: 16009956
    [No Abstract]   [Full Text] [Related]  

  • 14. Ovarian ablation as a treatment for breast cancer.
    Sainsbury R
    Surg Oncol; 2003 Dec; 12(4):241-50. PubMed ID: 14998564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrinology and hormone therapy in breast cancer: endocrine therapy in premenopausal women.
    Pritchard K
    Breast Cancer Res; 2005; 7(2):70-6. PubMed ID: 15743514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [LH-RH analogue for the treatment in premenopausal, receptor-positive breast cancer].
    Sano M; Makino H
    Nihon Rinsho; 2000 Apr; 58 Suppl():328-33. PubMed ID: 11026014
    [No Abstract]   [Full Text] [Related]  

  • 17. [Long-term results of adjuvant endocrine therapy for hormone receptor-positive breast cancer].
    Semilgazov VF; Manikhas AG; Semiglazov VV; Bozhok AA; Dashian GA; Ivanov VG; Paltuev RM; Vasil'ev AG; Shchedrin DE; Ermachenkova AM; Nikitina IV; Pen'kov KD; Bessonov AA; Tabagua TT; Kolar'kova VV
    Vopr Onkol; 2011; 57(5):567-77. PubMed ID: 22238925
    [No Abstract]   [Full Text] [Related]  

  • 18. The optimal duration of adjuvant hormonal therapy for early-stage breast cancer.
    Winer E
    Clin Adv Hematol Oncol; 2008 Aug; 6(8):573-4. PubMed ID: 18820598
    [No Abstract]   [Full Text] [Related]  

  • 19. [LHRH analogs in adjuvant endocrine therapy for pre-menopausal localized breast cancers: Ending the controversy for novel guidelines?].
    Daguenet E; Jmour O; Vallard A; Guy JB; Jacquin JP; Méry B; Magné N
    Bull Cancer; 2019 Apr; 106(4):342-353. PubMed ID: 30853114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant endocrine therapy for premenopausal women with early breast cancer.
    Bao T; Davidson NE
    Breast Cancer Res; 2007; 9(6):115. PubMed ID: 18190722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.